Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices

Kameyama, Yoshiko; Okazaki, Naomi; Nakagawa, Miho; Koshida, Hikaru; Nakamura, Masuhisa; Gemba, Munekazu

doi:10.1016/0378-4274(90)90161-e

Cited by 63 publications

(45 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nedaplatin has a short elimination half-life and a phamacokinetic profile similar to that of CBDCA (Sasaki et al, 1989). Nephrotoxicity and gastrointestinal toxicity often limits the clinical use of antitumour agents such as CDDP, but 254-S causes less nephrotoxicity and gastrointestinal toxicity than CDDP, although its haematological toxicity can be a limiting factor at high dosage, as found with CBDCA (Kameyama et al, 1990;Ota et al, 1992;Suzumura et al, 1989). The dose-limiting toxicity (DLT) of 254-S is myelosuppression, especially thrombocytopenia.…”

mentioning

confidence: 99%

Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer

Tsuda

Hashiguchi

Nishimura³

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

Combination chemotherapy with irinotecan (CPT-11) and platinum compounds is effective for treating cervical cancer. Nedaplatin (254-S) is a new cisplatin analogue that achieves a high response rate (53%) in patients with primary cervical cancer. We performed a phase I -II study of combination chemotherapy with CPT-11 plus 254-S for advanced or recurrent cervical cancer. The inclusion criteria were stage IV disease or recurrence. CPT-11 and 254-S were administered intravenously on day 1, while rhG-CSF (50 mg) was given on days 3 -12. This regimen was repeated after 4 weeks. Dose escalation was carried out in tandem (CPT-11/254-S: 50/70, 50/80, and 60/80 mg m À2 ). A total of 27 patients (stage IV ¼ seven, recurrence ¼ 20) were enrolled. The phase I study enrolled eight patients. At dose levels 1 and 2, no dose-limiting toxicities were observed. At dose level 3, the first two patients developed DLTs. The maximum tolerated dose of CPT-11 and 254-S was 60 and 80 mg m À2 , respectively, and the recommended doses were 50 and 80 mg m À2 . Grade 3/4 haematologic toxicity occurred in 67% in phase II study, but there were no grade 3 nonhaematologic toxicities except fot nausea or lethargy. In all 27 patients, there were two complete responses (7%) and 14 Partial responses (52%), for an overall response rate of 59% (95% confidence interval: 39 -78%). Among the 12 responders with recurrent disease, the median time to progression and median survival were 161 days (range: 61 -711 days) and 415 days (range: 74 -801 days). This new regimen is promising for cervical cancer.

show abstract

mentioning

confidence: 99%

Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer

Tsuda

Hashiguchi

Nishimura³

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Nedaplatin is a second-generation platinum derivative that has shown equivalent antitumour activity and lower toxicity -less nausea, and lower nephrotoxicity and neurotoxicity -than cisplatin (Kameyama et al, 1990;Ota et al, 1992). A phase I study demonstrated the maximum tolerated dose (MTD) and the recommended dose (RD) for phase II studies of nedaplatin was 120 and 100 mg m À2 , respectively, and the dose-limiting toxicity (DLT) was thrombocytopenia (Ota et al, 1992).…”

mentioning

confidence: 99%

Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer

et al. 2004

View full text Add to dashboard Cite

To establish the toxicities and maximum tolerated dose (MTD) of nedaplatin with gemcitabine, and to observe their antitumour activity, we conducted a combination phase I study in advanced non-small-cell lung cancer (NSCLC). Patients received nedaplatin (60 -100 mg m À2 given intravenously over 90 min) on day 1, and gemcitabine (800 -1000 mg m À2 given intravenously over 30 min) on days 1, 8, every 3 weeks. In total, 20 patients with locally advanced or metastatic NSCLC who received no prior chemotherapy or one previous chemotherapy regimen were enrolled. The most frequent toxicities were neutropenia and thrombocytopenia; nonhaematological toxicities were generally mild. Three out of six patients experienced dose-limiting toxicities (neutropenia, thrombocytopenia and delayed anaemia) at dose level 4, 100 mg m À2 nedaplatin with 1000 mg m À2 gemcitabine, which was regarded as the MTD. There were three partial responses, for an overall response rate of 16.7%. The median survival time and 1-year survival rate were 9.1 months and 34.1%, respectively. This combination is well tolerated and active for advanced NSCLC. The recommended dose is 80 mg m À2 nedaplatin with 1000 mg m À2 gemcitabine. This combination chemotherapy warrants a phase II study and further evaluation in prospective randomised trials with cisplatin-or carboplatin-based combinations as first-line chemotherapy for advanced NSCLC.

show abstract

“…Cisplatin is one of the most widely used platinum derivatives, however it is considered to link with significant toxicities, including severe nausea /vomiting, ototoxicity and neuropathy and renal toxicity, thus requiring adequate hydration. Nedaplatin is an analogue of cisplatin, with reported low neurotoxicity and nephrotoxicity, and high in vivo bioavailability (Kameyama et al, 1990).…”

Section: Discussionmentioning

confidence: 99%

“…Nedaplatin is an analogue of cisplatin, with relatively low neurotoxicity and nephrotoxicity, and high in vivo bioavailability, indicating an important role as a component in the regimens for treating patients with NSCLC (Kameyama et al, 1990). Previous phase I/II study of nedaplatin and irinotecan suggested a response rate (RR)of 31.0% in treating patients with NSCLC (Oshita et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with Non-small Cell Lung Cancer

Yang

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: This analysis was conducted to evaluate the efficacy and safety of a combination of gemcitabine and nedaplatin in treating patients with non-small cell lung cancer. Methods: Clinical studies evaluating the efficacy and safety of a combination of gemcitabine and nedaplatin with attention to response and safety for patients with non-small cell lung cancer were identified using a predefined search strategy. Pooled response rates for gemcitabine and nedaplatin were calculated. Results: In gemcitabine and nedaplatin based regimens, 4 clinical studies including 112 patients with non-small cell lung cancer were considered eligible for inclusion. The pooled analysis suggested that the pooled reponse rate was 40.2% (45/112). Main side effects included grade 3-4 neutropenia, thrombocytopenia, and anemia. Grade 3-4 nonhematological toxicity included nausea and vomiting, diarrhea, and hepatic dysfunction. There were no treatment-related deaths. Conclusion: This evidence based analysis suggests that the combination of gemcitabine and nedaplatin is associated with good response rate and accepted toxicity for treating patients with non-small cell lung cancer.

show abstract

Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices

Cited by 63 publications

References 15 publications

Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer

Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer

Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer

A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with Non-small Cell Lung Cancer

Contact Info

Product

Resources

About